Forensic Analysis · Health Care
Regeneron Pharmaceuticals Inc. Common Stock (REGN)
A forensic read on Regeneron Pharmaceuticals Inc. Common Stock built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
14.6
P / E
14.3%
ROE
$65.0B
Market cap
0.61%
Dividend yield
The full forensic report — free
🔒Every red flag on REGN, detailed and traced to the filing
🔒Altman Z distress & Beneish M earnings-quality screens
🔒Calibrated 12-month price forecast + reverse-DCF
🔒Earnings-quality & capital-allocation forensics
No credit card · informational only, not investment advice
← Browse all forensic stock analyses
Data from SEC EDGAR public filings. Forensic signals flag probability, not certainty.